^
Association details:
Biomarker:FANCA mutation
Cancer:Ovarian Cancer
Drug:Zejula (niraparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report

Published date:
02/25/2022
Excerpt:
A 49-year-old female patient without a family history of cancer was diagnosed with epithelial OC….The next-generation sequencing analysis results revealed a germline FANCA mutation in the tumor tissue….Subsequently, the third-line treatment of liposomal doxorubicin hydrochloride plus lobaplatin was administrated for five cycles with the patient’s consent. Then, oral niraparib (200 mg daily) was given for maintenance treatment. During the follow-up, no evidence of tumor recurrence was observed.
Secondary therapy:
doxorubicin hydrochloride + D19466
DOI:
https://doi.org/10.3389/fonc.2022.778545